UPDATE : Tuesday, August 11, 2020
상단여백
Labor-management dispute runs deep at MSD Korea by Kim Yun-mi 2020-06-23 12:06
‘Pfizer’s Vyndaqel, Vyndamax do not deserve rare disease pricing’ by Kim Yun-mi 2020-06-22 17:19
New diabetes drug Steglatro fails to prove cardiovascular benefit by Kim Yun-mi 2020-06-19 14:55
Yuyu to export SD Biosensor's Covid-19 test kit by Lee Han-soo 2020-06-19 14:48
HK inno.N nabs FDA nod for trial of gastric acid blocker by Lee Han-soo 2020-06-18 17:39
라인
AZ’s Imfinzi wins extra indication for small-cell lung cancer by Kim Yun-mi 2020-06-18 15:55
5 key factors in successful secondary packaging and device assembly strategy by Lee Han-soo 2020-06-18 15:52
Lilly beats Pfizer in treating early breast cancer by Kim Yun-mi 2020-06-18 14:44
‘Tecentriq, major turning point for triple-negative breast cancer treatment’ by Kim Yun-mi 2020-06-18 14:43
IOF aims to reduce osteoporosis-related fractures by 25% by 2025 by Kim Yun-mi 2020-06-17 14:28
라인
JW Pharma to recreate its anticancer therapy as Covid-19 drug by Shim Hyun-tai 2020-06-17 14:26
Sanofi releases hemophilia A treatment by Shim Hyun-tai 2020-06-16 17:27
Sillajen CEO steps down by Lee Han-soo 2020-06-16 16:49
MSD fails to present plausible reasons, grounds for discriminating against branches by Lee Han-soo 2020-06-16 16:21
Gemvax & Kael's GV1001 shows efficacy as hepatitis B treatment by Lee Han-soo 2020-06-16 16:18
라인
‘Celltrion has no reason to save Takeda Korea workers’ jobs’ by Kim Yun-mi 2020-06-16 11:44
Jardiance family of diabetes drugs sells ₩10 billion in Q1 by Kim Yun-mi 2020-06-15 17:39
Biogen’s FDA application for Alzheimer’s drug drags on by Kim Yun-mi 2020-06-15 12:09
Survey paints gloomy outlook for Korea’s developing Covid-19 treatment by Shim Hyun-tai 2020-06-12 17:56
PharmAbcine inks CDMO deal with Australian firm for immunotherapy candidate by Lee Han-soo 2020-06-12 17:15
여백
여백
여백
Back to Top